Open AccessTropomyosin receptor kinase inhibitors in the management of sarcomas
Author(s) -
Christopher P Wilding,
Herbert H. Loong,
Paul H. Huang,
Robin L. Jones
Publication year - 2020
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0000000000000650
Subject(s) - trk receptor , medicine , clinical trial , targeted therapy , oncology , cancer , neurotrophin , receptor
Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas are rare and there is a significant challenge in identifying patients with sarcomas harbouring TRK fusions in the clinical setting. Despite a recent European Society of Medical Oncology consensus article regarding screening of tumours for TRK fusions, economical and practical limitations present a barrier to widespread screening of sarcomas.